Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation-Reference-Cited by-同舟云学术

Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation

Published:2019-02-15 Issue:4 Volume:124 Page:539-552
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circ Res

Author:

Zhu Wandi¹,Mazzanti Andrea²,Voelker Taylor L.¹,Hou Panpan¹,Moreno Jonathan D.¹³,Angsutararux Paweorn¹,Naegle Kristen M.¹,Priori Silvia G.²⁴,Silva Jonathan R.¹

Affiliation:

1. From the Department of Biomedical Engineering (W.Z., T.L.V., P.H., J.D.M., P.A., K.M.N., J.R.S.), Washington University in St Louis, MO

2. Molecular Cardiology, IRCCS Salvatore Maugeri Foundation, Pavia, Italy (A.M., S.G.P.)

3. Division of Cardiology, Department of Medicine (J.D.M.), Washington University in St Louis, MO

4. Department of Molecular Medicine, University of Pavia, Italy (S.G.P.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference36 articles.

1. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.;Priori SG;Eur Heart J,2015

2. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3

3. Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients

4. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy;Archives of Cardiovascular Diseases;2024-06

2. Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome;eBioMedicine;2024-05

3. Ventricular Tachycardia Due to Triggered Activity;JACC: Clinical Electrophysiology;2023-12

4. Proof-of-concept for monoclonal antibody therapy in a cellular model of acquired long QT syndrome type 3;American Journal of Physiology-Heart and Circulatory Physiology;2023-11-10

5. Type 3 long QT syndrome: Is the effectiveness of treatment with beta-blockers population-specific?;Heart Rhythm;2023-11